AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$TWST

WERNER ROBERT F. sold $213K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 1,523 shares of Twist Bioscience Corp (TWST) at an average of $140.02 ($139.07–$140.77, $0.21M total) across 2 trades over 2026-08-21 to 2026-08-24.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Aug 25, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming financing or compensation events not disclosed.

Relevance 4/10Novelty 4/10Timing: post-filing

Background

Form 4 filings disclose insider transactions; traders monitor for signals.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Chief Accounting Officer sold 1,523 shares for $213K, reducing his stake to 44,637 shares.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of total holdings; market reaction likely limited.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

No regional effect.

Global

Limited to Twist Bioscience investors.

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; insider may need liquidity.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company listed on NASDAQ.

  • Insider
    Werner Robert F.

    Chief Accounting Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

AUG 23
$MRNAHighAI 9/10

Bond Jitters Meet Biotech Fireworks

Bond market volatility pressured stocks early in the week, with the Nasdaq dropping 2.1%. Biotech stocks surged: Moderna (MRNA) rose 177% after positive cancer trial results, and Twist Bioscience (TWST) gained 23% on AI-driven protein binder success. NVIDIA's earnings and the Jackson Hole symposium are upcoming market tests.

zerohedge.com3 min
AUG 21
$TWSTHighAI 8/10

Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook

Twist Bioscience (TWST) stock rose 6.79% on strong investor optimism. The company reported Q3 revenue of $118.4M, up 23% YoY, with a 78% gross margin but negative EBIT margin and ROE. Guidance was raised to $456M-$457M for FY26, with Q4 adjusted EBITDA breakeven expected. The stock has seen strong technical performance, with resistance near $150 and support at $130-$135.

stockstotrade.com2 min
AUG 19
$TWSTHighAI 8/10

Why is Twist Bioscience stock surging today?

Twist Bioscience (TWST) stock rose 15.3% after Anthropic's research highlighted its role in producing AI-designed proteins. The company filed an 8-K disclosing the collaboration, which supports its AI-driven drug discovery growth narrative. Shares reached a 52-week high of $141.10.

investing.com2 min